The early FDA approval doesn't change Pfizer and Arvinas' plan to leave commercialization of the drug to a yet-to-be-identified partner.
In today’s healthcare landscape, we speak often of the transformation of shifting from volume to value, from episodic care to longitudinal outcomes, from fragmentation to coordination. …
The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón.
A federal appeals court ruling restricts telemedicine access to the abortion drug mifepristone for the whole country, at least temporarily. But another drug that remains available …
White House National Economic Council (NEC) Director Kevin Hassett on Sunday said he was “very involved” in the Trump administration’s potential plan to bailout Spirit from …